It's a little premature to accuse someone of screwing up when they have enough cash and are working on partnering a low risk pivotal stage oncology drug. Based on recent deals, they should be able to pull it at least $50M upfront or more with a lot of biobucks. If they end up raising money this year in the $2s then we can conclude you were right.
Market Data 
Markets 
AI
